Category Archives: Muscular Dystrophy Treatment

Oct. 26, 2020 21:00 UTC -- PolarisDMD Trial Did Not Achieve Primary or Secondary Endpoints -- BOSTON--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc., Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, which was a change from baseline in the North Star Ambulatory Assessment (NSAA) over one year of edasalonexent compared to placebo Continue reading →

NEW YORK, Oct. 28, 2020 /PRNewswire/ --The Muscular Dystrophy Association (MDA) announced today the launch of the neuroMuscular ObserVational Research (MOVR) Visualization and Reporting Platform (VRP). The new platform represents a monumental leap in advancing neuromuscular disease research and improving patient care. Continue reading →

Shares of Catabasis Pharmaceuticals have plunged more than 64% in premarket trading following Mondays announcement the companys last-stage Duchenne muscular dystrophy treatment failed to meet the trials primary and secondary endpoints. The company will scrap the program and explore strategic options. On Monday, Boston-based Catabasis said its Phase III PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, which was a change from baseline in the North Star Ambulatory Assessment (NSAA) over one year of edasalonexent in comparison to placebo Continue reading →

No news on Pfizers Covid-19 vaccine is good news No news on Pfizers Covid-19 vaccine is good news and bad news The Road Ahead: Charting the coronavirus pandemic over the The Road Ahead: Charting the coronavirus pandemic over the next 12 months and beyond Long after the fire of a Covid-19 infection, mental Long after the fire of a Covid-19 infection, mental and neurological effects can still smolder Startup Spotlight: Encoded eyes a gene therapy for Dravet Startup Spotlight: Encoded eyes a gene therapy for Dravet syndrome Google and the Mayo Clinic to use AI to Google and the Mayo Clinic to use AI to better target radiation therapy Pharmalittle: Lilly signs $375 million deal with U.S. for Pharmalittle: Lilly signs $375 million deal with U.S. for Covid-19 drug; Sanofi and Glaxo will supply Continue reading →

Oct. 26, 2020 07:30 UTC BERLIN--(BUSINESS WIRE)-- Bayer AG today announced the acquisition of Asklepios BioPharmaceutical, Inc. (AskBio), a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies across different therapeutic areas. Continue reading →

PARIS andCAMBRIDGE, Massachusetts, Oct. Continue reading →

The Oculopharyngeal Muscular Dystrophy Treatment Market globally is a standout amongst the most emergent and astoundingly approved sectors. This worldwide market has been developing at a higher pace with the development of imaginative frameworks and a developing end-client tendency. Oculopharyngeal Muscular Dystrophy Treatment market reports deliver insight and expert analysis into key consumer trends and behaviour in marketplace, in addition to an overview of the market data and key brands Continue reading →

Its a day of firsts, with the launch of two new Cambridge, Mass.-based life sciences companies, Be Biopharma, with a focus on B cell malignancies, and AavantiBio, a gene therapy company aimed at treating rare genetic diseases. Continue reading →

Stanford researchers have several projects underway to improve imaging techniques, bracing treatment and surgeries for kids and teens with scoliosis. Scoliosis is a common condition in which the spine twists and curves sideways instead of running straight down the center of the back. More than 1 in every 100 adolescents is diagnosed with scoliosis, but it can also occur in younger children Continue reading →

The energetic 3-year-old boy toddled around the living room of his Longview home with a blanket over his head, announcing he was a ghost. Finn Florczykowskis mother explained that he is excited for Halloween since he is now old enough to be aware of the holiday. Over time, Finn will lose the ability to walk and also lose mobility in his arms and legs due to Duchenne muscular dystrophy, a rare and aggressive genetic disease that causes rapid muscular deterioration Continue reading →